Key Biotech Wins in 2025 and Strategic Priorities for Drug Developers in 2026

Biotech Wins: Oncology’s momentum continues into 2026

Oncology remained the most active therapeutic area in drug development throughout 2025, driven by numerous biotech wins and sustained innovation across immunotherapy, targeted therapies, cell and gene treatments, and precision medicine. 

Industry analysts, conference theses from major oncology meetings such as IO360, and banking outlook reports all point to a sector that not only delivered meaningful wins in 2025 but is also entering 2026 with a robust clinical pipeline and expanding investment interest.

With rising global cancer incidence and spending on cancer medicines projected to reach nearly $409 billion by 2028, oncology continues to command strategic priority among biotech innovators and large pharmaceutical companies alike.

2025 wins for oncology biotech’s

Strong regulatory activity and pipeline maturation

Despite macroeconomic pressures and regulatory complexity, oncology developers achieved notable regulatory progress in 2025. Approximately 46 new drugs were approved by the U.S. FDA during the year, with oncology accounting for about 35% of approvals, making it the leading therapeutic area.

Additionally, overall FDA approvals across therapeutic areas reached around 55 new products, demonstrating continued productivity across the biopharma ecosystem despite economic uncertainty.

Other indicators of biotech success in oncology during 2025 included:

• Increased use of accelerated pathways and breakthrough designations to bring therapies to patients faster.
  
• Continued growth in kinase inhibitors and targeted therapies among approved small molecules.
  
• Expanding partnerships between biotech innovators and large pharmaceutical companies to advance oncology assets, including multimillion-dollar collaboration agreements.
  

These wins highlight how emerging biotech’s continue to drive innovation while leveraging strategic alliances for global commercialization.

Market expansion across immuno-oncology and advanced modalities

Commercial success in oncology also accelerated in 2025. The global immuno-oncology market surpassed approximately $109 billion in value, reflecting strong adoption of checkpoint inhibitors, CAR-T therapies, and bispecific antibodies.

Meanwhile, T-cell therapy markets and advanced cell therapies showed strong growth projections, supported by an expanding pipeline of clinical candidates and increasing regulatory approvals.

Several key technology platforms delivered strong momentum in 2025:

• Antibody-drug conjugates (ADCs) and bispecific antibodies advanced into later-stage trials.
  
• Radiopharmaceuticals and precision oncology approaches gained increased investor attention.
  
• AI-driven drug discovery tools accelerated early-stage development processes.
  

These trends demonstrate that oncology innovation is shifting toward highly targeted, biomarker-driven treatments designed to improve outcomes while reducing toxicity.

Robust clinical activity signals sustained innovation

Clinical trial activity remained exceptionally strong throughout 2025, reflecting a healthy innovation pipeline. Analysts estimate that the oncology clinical trials market reached approximately $14.27 billion in 2025 and is expected to grow steadily through the next decade.

Key pipeline indicators include:

• More than 6,500 immuno-oncology trials projected to complete globally.
  
• Over 600 bispecific antibody candidates currently in development.
  
• More than 180 ADC programs advancing through clinical trials.
  

These figures illustrate a pipeline that is both diversified and technologically advanced, positioning oncology biotechs for continued innovation in the coming years.

2026 plans for oncology drug developers

Focus on precision medicine and targeted therapies

Drug developers are expected to double down on precision medicine strategies in 2026, leveraging genomic profiling and biomarker-driven trial designs. Targeted therapies already represent the fastest-growing oncology modality, with ADCs and multi-specific antibodies leading pipeline expansion.

Key priorities for 2026 include:

• Personalized combination therapies targeting multiple cancer pathways.
  
• Expansion into earlier lines of treatment and adjuvant settings.
  
• Integration of companion diagnostics and real-world evidence into regulatory submissions.
  

These approaches aim to improve patient outcomes while strengthening clinical differentiation in increasingly competitive therapeutic areas.

Increased adoption of AI and digital innovation in R&D

AI-driven technologies are reshaping oncology drug development, particularly in clinical trial recruitment, protocol design, and patient stratification. Automation and predictive analytics are expected to improve trial efficiency and reduce development timelines.

Developers are planning to:

• Utilize AI to identify optimal trial populations and biomarkers.
  
• Improve data integration across multi-omic datasets.
  
• Enhance decentralized trial models to increase global patient access.
  

This digital transformation is expected to improve both R&D productivity and commercial success rates in oncology pipelines.

Strategic partnerships and global collaboration

The growing complexity and cost of oncology development are driving increased collaboration between biotech innovators and established pharmaceutical companies. Strategic licensing deals, co-development agreements, and regional commercialization partnerships are expected to rise significantly in 2026.

Recent cross-border partnerships highlight how companies are combining scientific innovation with global development expertise to accelerate oncology programs and expand geographic reach.

Expanding investment and commercial strategy evolution

Banking analysts expect oncology to remain one of the most attractive therapeutic areas for venture capital and IPO activity. Average peak sales for novel drug approvals are forecast to reach around $1.2 billion, reflecting strong commercial potential.

Commercial strategies for 2026 will emphasize:

• Early access programs and accelerated approval pathways.

• Value-based pricing and real-world outcomes tracking.

• Portfolio diversification across rare cancers and high-prevalence tumor types.

Key takeaways for industry stakeholders

The oncology biotech sector demonstrated resilience and innovation in 2025, with strong regulatory performance, expanding markets, and a robust clinical pipeline. Heading into 2026, developers are expected to prioritize precision medicine, AI-driven R&D, and strategic collaborations to bring differentiated therapies to patients faster.

For investors, healthcare organizations, and drug developers, oncology remains a cornerstone of biopharma innovation, and a critical opportunity for advancing patient care.

As oncology pipelines grow more complex and competitive, stakeholders need clear strategies for navigating clinical development, regulatory landscapes, and commercialization challenges.

Connect with IAG to explore data-driven insights, strategic consulting, and end-to-end support for oncology drug development, from early-stage strategy to market access and commercialization.